Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation
Antineoplastic Combined Chemotherapy Protocols
Leukemia, Myeloid, Acute
Protein Kinase Inhibitors
fms-Like Tyrosine Kinase 3
The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 mutation. (Funded by the National Cancer Institute and Novartis; ClinicalTrials.gov number, NCT00651261 .).